1. Introduction
===============

Thiophene compounds are well known to exhibit various biological and medicinal activities such as BACE1 inhibitors \[[@b1-ijms-13-03661]\], antitubercular \[[@b2-ijms-13-03661]\], anti-depressant \[[@b3-ijms-13-03661]\], anti-inflammatory \[[@b4-ijms-13-03661]\], anti-HIV PR inhibitors \[[@b5-ijms-13-03661]\], and anti-breast cancer activities \[[@b6-ijms-13-03661]\]. In addition, thienothiophenes have potential applications in a wide variety of optical and electronic systems \[[@b7-ijms-13-03661]--[@b9-ijms-13-03661]\]. Furthermore, 1,3,4-thiadiazoles were recently reported as highly anti-inflammatory \[[@b10-ijms-13-03661],[@b11-ijms-13-03661]\], and anticonvulsant agents \[[@b10-ijms-13-03661],[@b12-ijms-13-03661]\]. Also, thiazoles and their derivatives found application in drug development for the treatment of allergies \[[@b13-ijms-13-03661]\], hypertension \[[@b14-ijms-13-03661]\], inflammation \[[@b15-ijms-13-03661]\], schizophrenia \[[@b16-ijms-13-03661]\], bacterial \[[@b17-ijms-13-03661]\] and HIV infections \[[@b18-ijms-13-03661]\]. Encouraged by all these findings and in continuation of our ongoing research program investigating the utilization of compound **1** as versatile and useful building blocks for the synthesis of a wide variety of bis-heterocycles systems \[[@b19-ijms-13-03661],[@b20-ijms-13-03661]\], we report in the present work an efficient and rapid method for the synthesis of a series of thienothiophene pendant to thiadiazole or thiazole moieties.

2. Results and Discussion
=========================

The nucleophilic addition of thieno\[2,3-*b*\]thiophene **1** \[[@b19-ijms-13-03661]\] to phenyl isothiocyanate in DMF, in the presence of potassium hydroxide, afforded the corresponding potassium salt **2**. Heterocyclisation of the intermediate **2** with hydrazonoyl chlorides **3a** \[[@b21-ijms-13-03661]\] or **3b--d** \[[@b22-ijms-13-03661]\] or **3e--g** \[[@b23-ijms-13-03661]\] furnished in each case, one isolable product (as tested by TLC). The reaction products were identified as bis-\[[@b1-ijms-13-03661],[@b3-ijms-13-03661],[@b4-ijms-13-03661]\]-thiadiazole structures **6a--g** ([Scheme 1](#f1-ijms-13-03661){ref-type="fig"}).

The structure of the products **6a--g** was determined from spectroscopic as well as elemental analytical data. Thus, compound **6a**, taken as a typical example, showed absorption bands at 1674 and 2199 cm^−1^ corresponding to C=O and C ≡ N groups, respectively. Its ^1^H NMR spectrum revealed the absence of CH~2~ protons of compound **1** and showed signals at δ 2.49 due to CH~3~ protons, in addition to an aromatic multiplet in the region δ 7.57--7.97. The aforementioned results indicate that the reaction proceeds via *S*-alkylation \[[@b24-ijms-13-03661]\] to give *S*-alkylated intermediate **4** which cyclized *in situ* under the employed reaction conditions to give intermediate **5**. Elimination of two aniline molecules from **5** gave the desired product **6** ([Scheme 1](#f1-ijms-13-03661){ref-type="fig"}).

Next, the reactivity of the potassium salt **2** towards 3-(2-bromoacetyl)-2*H*-chromen-2-one (**7**) \[[@b25-ijms-13-03661],[@b26-ijms-13-03661]\] was also investigated. Thus, treatment of potassium salt **2** with compound **7** gave one product that was identified as 3,3′-(3,4-dimethylthieno\[2,3-*b*\]thiophene-2,5-diyl)bis(3-oxo-2-(4-(2-oxo-2*H*-chromen-3-yl)-3-phenylthiazol-2(3*H*)-ylidene)propanenitrile) (**10**) as shown in [Scheme 2](#f2-ijms-13-03661){ref-type="fig"}. The reaction proceeds via nucleophilic displacement of bromide to give *S*-alkylated intermediate **8**, followed by nucleophilic addition of (PhNH) group to carbonyl group of chromen-2-one ring to give the respective intermediate **9**. Dehydration of the latter intermediate gave bis-thiazole derivative **10** as the final product. The IR spectrum of the isolated product showed absorption bands at 2195, 1647 and 1724 cm^−1^ due to nitrile function and carbonyl groups, respectively. Its ^1^H NMR spectrum showed singlet signal at *δ* 2.49 ppm due to methyl protons, in addition to aromatic multiplets in the region *δ* 7.02--8.6 ppm.

Similarly, treatment of the potassium salt **2** with ethyl 2-chloro-3-oxobutanoate afforded diethyl 2,2′-(2,2′-(3,4-dimethylthieno\[2,3-*b*\]thiophene-2,5-diyl)bis(1-cyano-2-oxoethan-2-yl-1-ylidene))bis(4- methyl-3-phenyl-2,3-dihydrothiazole-5-carboxylate) (**13**) as outlined in [Scheme 3](#f3-ijms-13-03661){ref-type="fig"}. The bis-thiazole structure **13** was confirmed from its elemental analyses and spectral data. The IR spectrum of compound **13** revealed absorption bands at 2206, 1713 and 1643 cm^−1^ due to nitrile function and two carbonyl groups, respectively. Its ^1^H-NMR spectrum showed a triplet signal at δ 1.30 (*J* = 7.2 Hz) due to CH~3~ protons, two singlet signal at δ 2.24 and 2.49 characteristics for two methyl protons, a quartet signal at δ 4.32 (*J* = 7.2 Hz) due to CH~2~ protons, in addition to an aromatic multiplet in the region δ 7.62. A proposed mechanism for the formation of the bis-thiazole structure **13** is depicted in [Scheme 3](#f3-ijms-13-03661){ref-type="fig"}. The foregoing spectral data supported the proposed structure **13** and ruled out the other bis-thiazole structure **14** ([Scheme 3](#f3-ijms-13-03661){ref-type="fig"}).

3. Experimental Section
=======================

All melting points were measured on a Gallenkamp melting point apparatus (Weiss-Gallenkamp, London, UK). The infrared spectra were recorded in potassium bromide disks on a pye Unicam SP 3300 and Shimadzu FT IR 8101 PC infrared spectrophotometers (Pye Unicam Ltd. Cambridge, England and Shimadzu, Tokyo, Japan, respectively). The NMR spectra were recorded on a BRUKER VX-500 NMR spectrometer (Varian, Palo Alto, CA, USA). ^1^H spectra were run at 500 MHz in deuterated dimethyl sulfoxide (DMSO-*d~6~*). Chemical shifts were related to that of the solvent. Elemental analyses were carried out at the Micro-analytical Center of Cairo University, Giza, Egypt. The biological evaluation of the products **6a--g** and **10** were carried out in the Medical Mycology Laboratory of the Regional Center for Mycology and Biotechnology of Al-Azhar University, Cairo, Egypt. Thieno\[2,3-b\]thiophene **1** \[[@b19-ijms-13-03661]\], and hydrazonoyl chlorides **3a** \[[@b21-ijms-13-03661]\], **3b--d** \[[@b22-ijms-13-03661]\], **3e--g** \[[@b23-ijms-13-03661]\], and 3-(2-bromoacetyl)-2*H*-chromen-2-one (**7**) \[[@b25-ijms-13-03661],[@b26-ijms-13-03661]\] were prepared following the literature procedure.

Reactions of Compound **1** with Hydrazonoyl Halides **3a** or **3b-d** or **3e-g** or 3-(2-bromoacetyl)-2Hchromen- 2-one (**7**)
---------------------------------------------------------------------------------------------------------------------------------

### General Procedure

To a stirred solution of potassium hydroxide (0.11 g, 2 mmol) in 20 mL DMF was added compound **1** (0.302 g, 1 mmol). After stirring for 30 min, phenyl isothiocyanate (0.27 g, 2 mmol) was added to the resulting mixture. Stirring was continued for 6 h, and then the appropriate hydrazonoyl chlorides **3a--g** (2 mmol) or 3-(2-bromoacetyl)-2*H*-chromen-2-one (**7**) (0.534 g, 2 mmol) or ethyl 2-chloro-3-oxobutanoate (0.329 g, 2 mmol) was added portion-wise over a period of 30 min. After the addition was complete, the reaction mixture was stirred for additional 12 h, during which the hydrazonoyl chloride or 3-(2-bromoacetyl)-2*H*-chromen-2-one went into solution and a yellow product precipitated. The solid product was filtered off, washed with EtOH and dried, Recrystallization from DMF/EtOH (3:1) afforded the corresponding bis-\[[@b1-ijms-13-03661],[@b3-ijms-13-03661],[@b4-ijms-13-03661]\]thiadiazole derivatives **6a--g** or bis-thiazole derivatives **10** or **13**, respectively.

#### 3,3′-(3,4-Dimethylthieno\[2,3-b\]thiophene-2,5-diyl)bis(2-(3,5-diphenyl-1,3,4-thiadiazol-2(3H)- ylidene)-3-oxopropanenitrile) (**6a**)

Yield (61%), m.p. 276 °C; IR (KBr) ν~max~: 2905 (aliphatic CH), 2199 (C ≡ N), 1674 (C=O) cm^−1;\ 1^H-NMR (DMSO-d~6~): δ2.49 (s, 6H, 2CH~3~), 7.57--7.97 (m, 20H, ArH). MS m/z (%): 775 (M^+^, 0.16), 774 (0.14), 471 (46.73), 304 (4.13), 77 (70.79). Anal. Calcd for C~42~H~26~N~6~O~2~S~4~ (774.95): C, 65.09; H, 3.38; N, 10.84. Found: C, 65.01; H, 3.45; N, 10.90%.

#### Diethyl 5,5′-(2,2′-(3,4-dimethylthieno\[2,3-b\]thiophene-2,5-diyl)bis(1-cyano-2-oxoethan-2-yl-1- ylidene))bis(4-phenyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate)(**6b**)

Yield (52%), m.p. \> 300 °C; IR (KBr) ν~max~: 2982 (aliphatic CH), 2199 (C≡N), 1744 and 1674 (2C=O) cm^−1;\ 1^H-NMR (DMSO-d~6~): *δ* 1.33 (s, 6H, 2CH~3~, *J* = 6.9 Hz), 2.49 (s, 6H, 2CH~3~), 4.44 (q, 4H, 2CH~2~, *J* = 6.9 Hz),7.53--7.92 (m, 10H, ArH). MS m/z (%): 767 (M^+^, 1.57), 167 (19.92), 149 (36.71), 77 (7.77). Anal. Calcd for C*~36~*H*~26~*N*~6~*O*~6~*S*~4~* (766.89): C, 56.38; H, 3.42; N, 10.96. Found: C, 56.30; H, 3.36; N, 10.88%.

#### Diethyl 5,5′-(2,2′-(3,4-dimethylthieno\[2,3-b\]thiophene-2,5-diyl)bis(1-cyano-2-oxoethan-2-yl-1- ylidene))bis(4-p-tolyl-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate) (**6c**)

Yield (66%), m.p. \> 300 °C; IR (KBr) ν~max~: 2986 (aliphatic CH), 2203 (C≡N), 1747 and 1674 (2C=O) cm^−1;\ 1^H-NMR (DMSO-d~6~): *δ* 1.35 (s, 6H, 2CH~3~, *J* = 7.0 Hz), 2.42 (s, 6H, 2CH~3~), 2.52 (s, 6H, 2CH~3~),4.46 (q, 4H, 2CH~2~, *J* = 7.0 Hz),7.41 (d, 4H, *J* = 8.0 Hz), 7.62 (d, 4H, *J*= 8.0 Hz). MS m/z (%): 793 (3.44), 222 (4.85), 221 (4.55), 167 (9.11), 91 (50.33), 77 (51.22). Anal. Calcd for C~38~H~30~N~6~O~6~S~4~ (794.94): C, 57.41; H, 3.80; N, 10.57. Found: C, 57.52; H, 3.88; N, 10.66 %.

#### Diethyl 5,5′-(2,2′-(3,4-dimethylthieno\[2,3-b\]thiophene-2,5-diyl)bis(1-cyano-2-oxoethan-2-yl-1- ylidene))bis(4-(4-chlorophenyl)-4,5-dihydro-1,3,4-thiadiazole-2-carboxylate)(**6d**)

Yield (53%), m.p. \> 300 °C; IR (KBr) ν~max~: 2986 (aliphatic CH), 2206 (C≡N), 1744 and 1674 (2C=O) cm^−1;\ 1^H-NMR (DMSO-d~6~): δ1.37 (s, 6H, 2CH~3~, *J* = 7.0 Hz), 2.52 (s, 6H, 2CH~3~), 4.47 (q, 4H, 2CH~2~, *J* = 7.0 Hz),7.73 (d, 4H, *J*= 10.0 Hz), 7.84 (d, 4H, *J* = 10.0 Hz). MS m/z (%): 835 (M^+^, 2.81), 334 (6.05), 168 (8.37), 112 (6.37), 111 (23.38), 77 (39.48). Anal. Calcd for C~36~H~24~Cl~2~N~6~O~6~S (835.78): C, 51.73; H, 2.89; N, 10.06. Found: C, 51.67; H, 2.79; N, 10.12%.

#### 3,3′-(3,4-Dimethylthieno\[2,3-b\]thiophene-2,5-diyl)bis(2-(5-acetyl-3-p-tolyl-1,3,4-thiadiazol-2(3H)- ylidene)-3-oxopropanenitrile)(**6e**)

Yield (52%), m.p. 240 °C; IR (KBr) ν~max~: 2199 (C≡N), 1690 and 1674 (2C=O) cm^−1;\ 1^H-NMR (DMSO-d~6~): *δ* 2.29 (s, 6H, 2CH~3~), 2.45 (s, 6H, 2CH~3~), 2.50 (s, 6H, 2CH~3~), 7.22 (d, 4H, *J* = 8.5 Hz), 7.33 (d, 4H, *J* = 8.5 Hz). MS m/z (%): 732 (0.04), 647 (0.06), 221 (2.03), 166 (1.33), 106 (100.0), 91, (58.18), 77 (84.54). Anal. Calcd for C~36~H~26~N~6~O~4~S~4~ (734.89): C, 58.84; H, 3.57; N, 11.44. Found: C, 58.77; H, 3.49; N, 11.38%.

#### 3,3′-(3,4-Dimethylthieno\[2,3-b\]thiophene-2,5-diyl)bis(2-(5-acetyl-3-(4-chlorophenyl)-1,3,4- thiadiazol-2(3H)-ylidene)-3-oxopropanenitrile)(**6f**)

Yield (49%), m.p. 295 °C; IR (KBr) ν~max~: 2199 (C≡N), 1693 and 1655 (2C=O) cm^−1;\ 1^H-NMR (DMSO-d~6~): *δ* 2.41 (s, 6H, 2CH~3~), 2.52 (s, 6H, 2CH~3~), 7.72 (d, 4H, *J* = 8.8 Hz), 7.84 (d, 4H, *J* = 8.8 Hz). MS m/z (%): 776 (3.02), 500 (3.36), 471 (9.6), 304 (3.99), 276 (6.27), 166 (10.71), 112 (6.32), 111 (16.73). Anal. Calcd for C~34~H~20~Cl~2~N~6~O~4~S~4~ (775.73): C, 52.64; H, 2.60; N, 10.83. Found: C, 52.58; H, 2.54; N, 10.77%.

#### 3,3′-(3,4-Dimethylthieno\[2,3-b\]thiophene-2,5-diyl)bis(2-(5-acetyl-3-(3-chlorophenyl)-1,3,4- thiadiazol-2(3H)-ylidene)-3-oxopropanenitrile)(**6g**)

Yield (49%), m.p. \> 300 °C; IR (KBr) ν~max~: 2199 (C≡N), 1690 and 1647 (2C=O) cm^−1;\ 1^H-NMR (DMSO-d~6~): *δ*1.89 (s, 6H, 2CH~3~), 2.49 (s, 6H, 2CH~3~), 6.97--8.00 (m, 8H, ArH). MS m/z (%): 771 (3.28), 304 (6.34), 166 (22.08), 112 (13.36), 111 (18.98). Anal. Calcd for C~34~H~20~Cl~2~N~6~O~4~S~4~ (775.73): C, 52.64; H, 2.60; N, 10.83. Found: C, 52.55; H, 2.52; N, 10.74%.

#### 3,3′-(3,4-Dimethylthieno\[2,3-b\]thiophene-2,5-diyl)bis(3-oxo-2-(4-(2-oxo-2H-chromen-3-yl)-3- phenylthiazol-2(3H)-ylidene)propanenitrile) (**10**)

Yield (68%), m.p. \> 300 °C; IR (KBr) ν~max~: 2195 ((C≡N)), 1724 and 1647 (2C=O) cm^−1;\ 1^H-NMR (DMSO-d~6~): *δ* 2.49 (s, 6H, 2CH~3~), 7.02--8.6 (m, 22H, ArH). MS m/z (%): 909 (2.45), 166 (2.75), 145 (4.05), 77 (15.41). Anal. Calcd for C~50~H~28~N~4~O~6~S~4~ (909.04): C, 66.06; H, 3.10; N, 6.16. Found: C, 66.15; H, 3.21; N, 6.25%.

#### Diethyl 2,2′-(2,2′-(3,4-dimethylthieno\[2,3-b\]thiophene-2,5-diyl)bis(1-cyano-2-oxoethan-2-yl-1- ylidene))bis(4-methyl-3-phenyl-2,3-dihydrothiazole-5-carboxylate) (**13**)

Yield (44%), m.p. 278--280 °C; IR (KBr) ν~max~: 2986 (aliphatic CH), 2206 ((C≡N)), 1713 and 1643 (2C=O) cm^−1;\ 1^H-NMR (DMSO-d~6~): *δ* 1.30 (t, 6H, 2CH~3~, *J* = 7.2 Hz), 2.24 (s, 6H, 2CH~3~), 2.49 (s, 6H, 2CH~3~), 4.32 (q, 4H, 2CH~2~, *J* = 7.2 Hz),7.62 (s, 10H, ArH). Anal. Calcd for C~40~H~32~N~4~O~6~S~4~ (792.97): C, 60.59; H, 4.07; N, 7.07. Found: C, 60.48; H, 4.16; N, 7.15%.

3.1. Antimicrobial Evaluation
-----------------------------

The newly synthesized target compounds (**6a--g** and **10**) were evaluated for their *in vitro* antibacterial activity against *Staphylococcus aureus* (SA) and *Bacillis subtilis* (BS) as examples of Gram-positive bacteria and *Pseudomonas aeruginosa* (PA) and *Escherichia coli* (EC) as examples of Gram-negative bacteria. They were also evaluated for their *in vitro* antifungal potential against *Aspergillus fumigatus* (AF), *Geotrichum candidum* (GC), *Candida albicans* (CA) and *Syncephalastrum racemosum* (SR) fungal strains. The organisms were tested against the activity of solutions of concentrations (5 μg/mL) and using inhibition zone diameter (IZD) in mm as criterion for the antimicrobial activity (agar diffusion method). The fungicides *Itraconazole*, *Clotrimazole* and the bactericides *Penicillin G, Streptomycin* were used as references to evaluate the potency of the tested compounds under the same conditions. The results are depicted in [Table 1](#t1-ijms-13-03661){ref-type="table"}.

The results depicted in [Table 1](#t1-ijms-13-03661){ref-type="table"} revealed that most of the tested compounds displayed variable inhibitory effects on the growth of the tested Gram-positive bacteria and Gram-negative bacteria strains and also against fungal strains. In general, most of the tested compounds revealed better activity against the Gram-positive bacteria rather than the Gram-negative bacteria: Compounds **6a**, **6c--d** and **10** exhibited almost no activity against *Syncephalastrum racemosum* and *Pseudomonas aeruginosa*; Compounds **6b** and **6e--g** exhibited almost no activity against *Candida albicans*. Compounds **6e** and **6g** exhibited almost no activity against *Pseudomonas aeruginosa*; Compounds **6d**, **6f** and **10** showed comparatively good activity against all the bacterial and fungal strains. The good activity of **6d** and **6f** is attributed to the presence of pharmacologically active 4-chlorophenyl at position 4 of the thiadiazole ring.

4. Conclusions
==============

In conclusion, the reactivity of diethyl 3,3′-(3,4-dimethylthieno\[2,3-*b*\]thiophene-2,5-diyl)bis (3-oxopropanenitrile) (**1**) was investigated as a versatile and readily accessible building block for the synthesis of new bis-heterocycles incorporating thieno\[2,3-*b*\]thiophene moiety of biological and pharmaceutical importance.
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###### 

Antibacterial and antifungal activities of the synthesized compounds (**6a--g**) and **10**.

  Sample/Tested Organism                6a                 6b                 6c            6d            6e            6f            6g            10            Standard      
  ------------------------------------- ------------------ ------------------ ------------- ------------- ------------- ------------- ------------- ------------- ------------- -------------
  ***Aspergillus fumigatus*(AF)**       11.7 ± 0.2         15.4 ± 0.09        13.3 ± 0.2    16.4 ± 0.3    9.3 ± 0.2     17.4 ± 0.08   12.2 ± 0.09   14.3 ± 0.2    28.5 ± 0.05   26 ± 0.1
  ***Geotrichum candidum*(GC)**         13.5 ± 0.1         14.9 ± 0.05        14.4 ± 0.1    18.1 ± 0.08   11.4 ± 0.1    18.3 ± 0.3    14.4 ± 0.03   16.7 ± 0.08   27.1 ± 0.06   23.1 ± 0.03
  ***Candida albicans*(CA)**            10.4 ± 0.08        NA                 10.2 ± 0.09   13.7 ± 0.05   NA            NA            NA            11.9 ± 0.1    26.1 ± 0.02   18.3 ± 0.01
  ***Syncephalastrum racemosum*(SR)**   NA                 12.1 ± 0.08        NA            NA            8.2 ± 0.09    14.2 ± 0.08   9.2 ± 0.08    NA            22.3 ± 0.09   20.5 ± 0.02
  ***Gram Positive Bacteria***          **Penicillin G**   **Streptomycin**                                                                                                     
  ***Staphylococcus aureus*(SA)**       11.2 ± 0.1         17.9 ± 0.05        11.3 ± 0.05   15.4 ± 0.5    9.4 ± 0.05    18.9 ± 0.01   13.8 ± 0.1    13.4 ± 0.3    29.4 ± 0.08   25.1 ± 0.08
  ***Bacillis subtilis*(BS)**           13.7 ± 0.07        16.1 ± 0.01        9.0 ± 0.08    18.4 ± 0.1    10.6 ± 0.08   20.9 ± 0.03   16.6 ± 0.03   14.7 ± 0.09   32.5 ± 0.06   29.1 ± 0.04
  ***Gram Negative Bacteria***          **Penicillin G**   **Streptomycin**                                                                                                     
  ***Pseudomonas aeruginosa*(PA)**      NA                 10.1 ± 0.01        NA            NA            NA            12.1 ± 0.01   NA            NA            28.3 ± 0.05   24.3 ± 0.08
  ***Escherichia coli*(EC)**            8.3 ± 0.09         14.5 ± 0.2         10.1 ± 0.07   13.7 ± 0.05   7.4 ± 0.07    15.2 ± 0.5    9.5 ± 0.2     10.9 ± 0.2    33.5 ± 0.7    25.6 ± 0.04

NA: No activity, data are expressed in the form of mean ± SD. Mean zone of inhibition in mm ± Standard deviation beyond well diameter (6 mm) produced on a range of environmental and clinically pathogenic microorganisms using (5 mg/mL) concentration of tested samples.
